|
411 Companies |
|
276 Products |
|
276 Products |
|
144 Mechanisms of Action |
|
556 Trials |
|
45670 News |
|
| «12...620621622623624625626627628629630...643644» |
- || Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment closed: A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel (clinicaltrials.gov) - Mar 4, 2014
P1, N=100, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting
- ||| lenalidomide / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Combination therapy: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Mar 4, 2014
P1/2, N=59, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| tovetumab (MEDI-575) / AstraZeneca
Trial completion, Combination therapy, Metastases: A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 4, 2014
P1/2, N=123, Completed, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Cubicin (daptomycin) / Merck (MSD)
Trial termination: Daptomycin Versus Placebo in Patients With Neutropenia and Fever (clinicaltrials.gov) - Mar 3, 2014
P3, N=36, Terminated, Sponsor: University of Rochester
Active, not recruiting --> Completed Recruiting --> Terminated; The study has shown futility and the objectives could not be reached without enrolling a very large number of subjects.
- Cubicin (daptomycin) / Merck (MSD)
Enrollment change: Daptomycin Versus Placebo in Patients With Neutropenia and Fever (clinicaltrials.gov) - Mar 3, 2014
P3, N=36, Terminated, Sponsor: University of Rochester
Recruiting --> Terminated; The study has shown futility and the objectives could not be reached without enrolling a very large number of subjects. N=100 --> 36
- Clinical: A Prospective Study on Effect of Systemic Adjuvant Therapy on Cognitive and Brain Function of Breast Cancer Patients (clinicaltrials.gov) - Mar 3, 2014
P=N/A, N=130, Not yet recruiting, Sponsor: National University Hospital, Singapore
- ||| PF-06647263 / Pfizer
New P1 trial, Metastases: A Study Of PF-06647263 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 3, 2014
P1, N=100, Recruiting, Sponsor: Pfizer
- Avastin (bevacizumab) / Roche
Enrollment change, Metastases: G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 2, 2014
P2, N=20, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
N=100 --> 36 N=30 --> 20
- ||| oprozomib (ONX 0912) / Amgen
Clinical: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 2, 2014
P1/2, N=314, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
N=30 --> 20 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 2, 2014
P2, N=20, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- plerixafor / Generic mfg.
Enrollment change: Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 26, 2014
P1/2, N=39, Active, not recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Completed N=76 --> 39
- New P2 trial: LYDIA: "LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia (clinicaltrials.gov) - Feb 26, 2014
P2, N=10, Recruiting, Sponsor: Hospital Universitario La Paz
- plerixafor / Generic mfg.
Enrollment closed: Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 26, 2014
P1/2, N=39, Active, not recruiting, Sponsor: Washington University School of Medicine
N=76 --> 39 Recruiting --> Active, not recruiting
- || Enrollment closed: Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy. (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=1009, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial: A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 23, 2014
P2, N=72, Recruiting, Sponsor: Hoffmann-La Roche
- Enrollment open, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: MOST plus: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (clinicaltrials.gov) - Feb 23, 2014
P2, N=560, Recruiting, Sponsor: Centre Leon Berard
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | cytarabine / Generic mfg., decitabine / Generic mfg.
Enrollment open: A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 23, 2014
P2, N=27, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| azacitidine / Generic mfg.
Trial completion: Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 22, 2014
P2, N=151, Completed, Sponsor: Celgene Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| imatinib / Generic mfg., dasatinib / Generic mfg.
Trial completion: Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib (clinicaltrials.gov) - Feb 22, 2014
P2, N=387, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | lapatinib / Generic mfg.
Trial completion: Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Combination therapy, Surgery: Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=590, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | lenalidomide / Generic mfg.
Trial completion: A Phase II Study of CC-5013 in Myelofibrosis (clinicaltrials.gov) - Feb 22, 2014
P2, N=41, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Triapine (3-AP) / Vion, Northwestern University
Trial completion: Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Triapine (3-AP) / Vion, Northwestern University
Trial completion: 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion: Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 22, 2014
P1, N=80, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Feb 22, 2014
P2, N=132, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Anidulafungin in Treating Immunocompromised Children With Neutropenia (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed No longer recruiting --> Completed
- | voriconazole / Generic mfg.
Trial completion: Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| lorvotuzumab mertansine (IMGN901) / AbbVie
Trial completion: Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=64, Completed, Sponsor: ImmunoGen, Inc.
No longer recruiting --> Completed Recruiting --> Completed
- | alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion, Combination therapy: Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=22, Completed, Sponsor: Virginia Commonwealth University
Recruiting --> Completed No longer recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Surgery, Post-surgery: Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed No longer recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed No longer recruiting --> Completed
- | Genasense (oblimersen) / Genta
Trial completion: Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=55, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | gefitinib / Generic mfg., capecitabine / Generic mfg., celecoxib oral / Generic mfg.
Trial completion: Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=41, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed
- | ABT-751 / AbbVie, Eisai
Trial completion: ABT-751 in Treating Young Patients With Refractory Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=90, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Suspended --> Completed Active, not recruiting --> Completed
- | Ixempra (ixabepilone) - Otsuka, R / Pharm
Trial completion, Metastases: Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck (clinicaltrials.gov) - Feb 22, 2014
P2, N=144, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | hydroxychloroquine / Generic mfg.
Trial completion: Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Feb 22, 2014
P3, N=82, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
Trial completion: Valganciclovir in Congenital CMV Infants (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | bortezomib / Generic mfg., paclitaxel / Generic mfg.
Trial completion: Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| oprozomib (ONX 0912) / Amgen
Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Feb 20, 2014
P1/2, N=118, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Active, not recruiting --> Completed N=59 --> 118
- pegvorhyaluronidase alfa (PEGPH20) / Halozyme
Enrollment open, Metastases: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 20, 2014
P1/2, N=172, Recruiting, Sponsor: Southwest Oncology Group
N=59 --> 118 Not yet recruiting --> Recruiting
- ||||||| Ziextenzo (pegfilgrastim-bmez) / Sandoz
Trial completion: PROTECT2: Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim (clinicaltrials.gov) - Feb 20, 2014
P3, N=308, Completed, Sponsor: Sandoz
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion: Bevacizumab in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion, Metastases: Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed Recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Benzoylphenylurea in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1, N=19, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Trial completion: Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease (clinicaltrials.gov) - Feb 19, 2014
P2, N=32, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed No longer recruiting --> Completed
- | amphotericin b liposome / Generic mfg., voriconazole / Generic mfg.
Trial completion: A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=866, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- | amphotericin b liposome / Generic mfg.
Trial completion: Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed